Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

THA CLINICAL HALT: WARNER-LAMBERT TO MEET WITH FDA THE WEEK OF NOV. 2

Executive Summary

THA CLINICAL HALT: WARNER-LAMBERT TO MEET WITH FDA THE WEEK OF NOV. 2 to discuss the possible resumption of THA clinical trials in Alzheimer's disease, Warner-Lambert told "The Pink Sheet." The company suspended studies on Oct. 23 when elevated liver enzyme levels appeared in certain patients. Warner-Lambert explained that liver toxicity was discovered in some patients taking the second-highest out of a total of four THA (tetrahydroaminoacridine) dosing regimens. The firm at this point feels the incidents were dose related. W-L said it will present all relevant data to FDA at the upcoming meeting. Approximately 40-50 patients at 12 centers have been enrolled in the trial during its first month, Warner-Lambert noted. Announced Aug. 6, the two-year program to test the safety and efficacy of THA in Alzheimer's Disease is expected to include about 300 patients at 17 centers. Warner-Lambert is supplying the drug along with $3 mil. in funding. An additional $1.9 mil. of funding comes from the National Institute on Aging, with another $250,000 donated from the Alzheimer's Disease and Related Disorders Association. At the time of the August announcement, HHS said that while the cooperatively funded trial has a two-year time frame, the study would "be monitored periodically to look for any beneficial or adverse effects of the drug." At the time, the department said that it expects to know "within a year" whether the drug might benefit Alzheimer's patients.

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

UsernamePublicRestriction

Register

PS051363

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel